The multifunctional growth factor scatter factor/hepatocyte growth factor (SF/HGF) and its receptor c-met have been implicated in the genesis, malignant progression, and chemo/radioresistance of multiple human malignancies, including gliomas. We examined the antitumor effects of targeting SF/HGF and c-met expression in pre-established glioma xenografts by using novel chimeric U1snRNA/ribozymes. Transient expression of anti-SF/HGF and anti-c-met U1snRNA/ribozymes inhibited SF/HGF and c-met expression, c-met receptor activation, tumor cell migration, and anchorage-independent colony formation in vitro. Delivery of U1snRNA/ribozymes to established subcutaneous glioma xenografts via liposome-DNA complexes significantly inhibited tumor growth as well as tumor SF/HGF and c-met expression levels. Histologic analysis of tumors treated with U1snRNA/ribozymes showed a significant decrease in blood vessel density, an increase in activation of the pro-apoptotic enzyme caspase-3, and an increase in tumor cell apoptosis. Treatment of animals bearing intracranial glioma xenografts with anti-SF/HGF and anti-c-met U1snRNA/ribozymes by either intratumoral injections of adenoviruses expressing the transgenes or intravenous injections of U1snRNA/ribozyme-liposome complexes substantially inhibited tumor growth and promoted animal survival. We demonstrate that SF/HGF and/or c-met expression can be targeted in vivo to inhibit tumor growth. In addition, our findings represent the first in vivo application of chimeric U1snRNA/ribozymes, which have numerous potential therapeutic genetargeting applications.
T he multifunctional growth factor scatter factor/hepatocyte growth factor (SF/HGF) and its tyrosine kinase receptor the protooncogene product c-met play important roles in tumorigenesis and malignant progression of a wide variety of human malignancies. c-Met expression is elevated in various human neoplasms, including gliomas, meningiomas, uveal melanoma, thyroid carcinoma, breast carcinoma, gastric carcinoma, hepatocarcinoma, colorectal cancer, and sarcomas (1) (2) (3) (4) (5) (6) (7) (8) . Transgenic mice overexpressing SF/HGF develop tumors in a wide variety of tissues, including breast, skin, liver, and salivary glands (9) . Also, activating mutations of c-met are oncogenic in human papillary renal carcinoma and may contribute to other human malignancies (10, 11) . In human and rodent gliomas, overexpression of SF/HGF enhances tumorigenicity and growth (12, 13) .
In addition to these correlative and gain-of-function studies, we recently established a role for SF/HGF-c-met signaling in glioma malignancy by showing that inhibiting endogenous SF/HGF and c-met expression in human glioblastoma cells reversed their malignant phenotype (14) . Strong inhibition of SF/HGF and c-met gene expression was achieved by stably transfecting cells with a newly developed chimeric transgene (designated U1/ribozyme) consisting of a combination of U1snRNA, hammerhead ribozyme, and antisense sequences (14, 15) (Fig. 1A ). These findings, in addition to a more recent study showing that anti-c-met U1/ribozymes inhibit SF/HGF-mediated cytoprotection against cytotoxic agents, establish SF/HGF and c-met as potential therapeutic targets in human gliomas (16) . This study was aimed at inhibiting SF/HGF and c-met expression in established human glioblastoma xenografts by in vivo delivery of U1/ribozymes via liposome-DNA complexes and adenoviruses. We studied the effects of anti-SF/HGF and anti-c-met U1/ribozyme delivery on in vivo SF/HGF and c-met expression, receptor activation, tumor growth, apoptosis, angiogenesis, animal survival, and other malignancy parameters.
MATERIALS AND METHODS

Adenovirus construction and liposome preparation
U1snRNA/ribozymes designed to inhibit SF/HGF and c-met expression were constructed as previously described (14) . In brief, two complementary pairs of antisense/ribozyme sequences, chosen to cleave the targeted mRNA immediately 3' of the GUC ribozyme cleavage consensus sequence at positions 701 for human SF/HGF and 560 for human c-met, were synthesized and annealed. The antisense/ribozyme duplexes were then ligated into the pZeoU1EcoSpe parent vector, which is derived from wild-type U1snRNA and is driven by the endogenous U1 promoter (15) . We analyzed the sequence of the resulting chimeric RNA with a computer program that predicts RNA secondary structure to ensure a maximal preservation of the U1snRNA stem loops, the ribozyme secondary structure, and the accessibility of the antisense sequence to the target mRNA (17) .
Replication-defective adenoviral vectors were constructed according to the method of Vogelstein and colleages (18) . In brief, U1/ribozyme transgenes were subcloned into the pAdTrack shuttle vector expressing a green fluorescent protein reporter transgene. pAdTrack was cotransfected with pAdEasy viral DNA into BJ5183 bacteria for homologous recombination. Recombinants were then transfected into 293 embryonic kidney cells for production of adenoviruses that were purified by ultracentrifugation and dialysis. Viral titers determined by plaque formation assays were ~10 12 pfu. Endotoxin-free plasmid DNA, complexed with liposomes containing the cationic lipid DOTIM (1- 
Northern hybridization and real-time reverse transcriptase-polymerase chain reaction (RT-PCR)
We isolated total RNA by using the RNeasy TM Mini Kit (Qiagen, Valencia, CA) following the manufacturer's instructions. Northern blot analysis was performed as previously reported (14) . Blots were hybridized with cDNA probes for c-met (1.3 kb), SF/HGF (1kb), and GAPDH (1.9kb) labeled with [ 32 P]dCTP by random priming (Roche Molecular Biochemicals, Indianapolis, IN). Radioactivity was quantified by densitometry and by phosphorimaging with the Bio-Imaging analyzer BAS 2500 (Fuji Medical Systems, Stamford, CT). All blots were stripped and then rehybridized with cDNA specific for GAPDH. Results were expressed relative to GAPDH mRNA.
Light Cycler PCR (Roche Molecular Biochemicals) was conducted with the FastStart SYBR Green I DNA Light Cycler kit according to the manufacturer's instructions. In brief, cDNA was generated from total tumor RNA by reverse transcription and PCR performed in the presence of SYBR Green I dye and either SF/HGF-or c-met-specific oligonucleotide primers. Primer sequences were 5'-GTTCCATGATACCACACG-3' and 5'-GATAACTCTCCCCATTGC-3' for SF/HGF, 5'-CAGGCAGTGCAGCATGTAGT-3' and 5'-GATGATTCCCTCGGTCAGAA-3' for c-met, and 5'-GGTGAAGGTCGGAGTCAACG-3' and 5'-CAAAGTTGTCATGGATGACC-3' for GAPDH. We analyzed PCR products by agarose gel electrophoresis to ensure the specifity of amplified DNA.
Immunoblotting and immunoprecipitation
We isolated cell extracts and performed immunoblot analysis, as previously described (14) , by using anti-c-met antibodies (Santa Cruz Biotechnologies, Santa Cruz, CA) or anti-SF/HGF antibodies. Immunoblots were quantified by densitomety and normalized to total protein loaded per lane. c-Met protein was immunoprecipitated from total cell extracts with anti-c-met antibodies (Santa Cruz Biotechnologies) by using a sepharose A/G immunoprecipitation kit (Roche Molecular Biochemicals) according to the manufacturer's instructions. Immunoprecipitates were separated by SDS-PAGE and subjected to immunoblot analysis using c-met and phospho-tyrosine antibodies (Santa Cruz Biotechnologies). Tyrosine phosphorylation was quantified by densitometry and expressed relative to total c-met protein.
Colony formation and cell migration assays
We cultured human glioblastoma U-87 MG cells and examined anchorage-independent colony formation, as previously described (14) . In brief, U-87 MG cells were transfected with Ad-U1/SF, Ad-U1/Met, or Ad-U1 for 48 h (multiplicity of infection [MOI]=10). Cells were then plated in soft agar and incubated for 3 wk at 37°C . Colonies >100 µm were quantified by computer-assisted image analysis.
For cell migration studies, we plated U-87 MG cells on grid-containing plates and treated them with Ad-U1/SF, Ad-U1/Met, or Ad-U1 for 48 h (MOI=10). We tested various MOI levels and time points in preliminary experiments to achieve infection of all cells (monitored by green fluorescence) without any visible toxicity signs. We then scraped away cells from a central strip of the plate and left the remaining cells to migrate into the central strip for 3 days. The number of cells that migrated a distance of >2 mm was determined and expressed as migration index.
In vivo U1/ribozyme delivery
For s.c. tumors, U-87 MG human glioblastoma cells (5 × 10 6 cells) were implanted s.c. into the flanks of Nu/Nu immunodeficient mice. When the tumors reached a size of ~50 mm 3 , they were injected directly with liposomes complexed with either pU1/SF, pU1/Met, or pU1 (100 µg total DNA in 50 µl) or with liposomes only twice a week for 21 days. Tumor sizes were measured before each injection. Alternatively, animals were treated by i.v. injection into the tail vein with liposomes complexed with either pU1/SF, pU1/Met, pU1/SF+pU1/Met, or pU1 (30 µg total DNA in 100 µl) every 10 days for 30 days. We used calipers to directly measure tumor size and calculated volume by using the following formula: volume = (length × width 2 )/2 (13).
For intracranial tumors, U-87 MG cells (1 × 10 5 ) were stereotactically implanted into the striatum of nude mice. Beginning 4 days postimplantation, animals were treated either with direct intratumoral injections of Ad-U1/SF+Ad-U1/Met or Ad-U1 (10 µl every 5 days; pfu = 10 12 ) and sacrificed at day 18 or with i.v. injections of pU1/SF+pU1/Met or pU1 liposomes (30 µg total DNA in 100 µl) every 10 days and sacrificed at day 18. The brains were removed, sectioned, and stained with hematoxylin and eosin. We determined maximal tumor cross-sectional area by using computer-assisted image analysis.
For survival studies, U-87 MG cells were implanted intracranially into nude mice, and the animals received liposome-DNA complexes i.v. every 10 days as described previously. Animals were left to die from tumors, and Kaplan-Meier survival curves were established.
Histological analyses
Histological sections from 4% paraformaldehyde perfusion fixed tumors were subjected to immunohistochemistry by using the ABC ELITE visualization method (Vector Laboratories, Burlingame, CA). Activated caspase-3, a marker for cellular apoptosis, was detected using a cleaved caspase-3 antibody (Cell Signaling Technology, Beverly, MA). We determined the apoptotic index by quantifying the number of caspase-3-positive cells per microscopic field. Tumor blood vessels were visualized using laminin antibody (Life Technologies, Rockville, MD) and quantified as total vessel area relative to tumor cross-sectional area as previously described (13) .
RESULTS
Adenovirus-mediated delivery of U1/ribozymes inhibits SF/HGF and c-met expression and activation
We and others have previously shown that stable expression of U1/ribozymes can effectively inhibit targeted gene expression (14, 15) . However, in vivo delivery of U1/ribozymes requires that they inhibit gene expression and generate biological responses under conditions of transient expression.
To test the effect of transient U1/ribozyme delivery on SF/HGF and c-met expression, we treated U-87 MG human glioblastoma cells with adenoviruses expressing anti-SF/HGF U1/ribozymes (Ad-U1/SF) and anti-c-met U1/ribozymes (Ad-U1/Met) as well as controls expressing U1snRNA only (Ad-U1) for 48 h and quantified mRNA and protein levels by Northern and immunoblotting, respectively. Adenovirus-based U1/ribozyme gene delivery led to a reduction of SF/HGF and c-met mRNA levels by 97% and 75% (n=2), respectively (Fig. 1B) . SF/HGF and c-met protein levels were decreased by 47% and 50% (n=2), respectively (Fig. 1C) . To study the effects of transient U1/ribozyme expression on SF/HGF-dependent functional c-met receptor activation, we examined the effect of Ad-U1/SF on c-met tyrosine phosphorylation in U-87 MG cells that express a SF/HGFc-met autocrine loop. U-87 MG cells were infected with Ad-U1/SF or control Ad-U1 for 48 h, after which total cellular c-met protein was immunoprecipitated and analyzed for c-met tyrosine phosphorylation by immunoblotting. Inhibition of SF/HGF expression by Ad-U1/SF reduced c-met tyrosine phosphorylation by 45% (n=2) relative to total c-met protein (Fig. 1D) .
Adenovirus-mediated delivery of U1/ribozymes inhibits tumor cell migration and colony formation in soft agar
To study the effects of transient expression of U1/ribozymes on the malignant phenotype in vitro, we treated U-87 MG cells with Ad-U1/SF, Ad-U1/Met, or Ad-U1 control for 48 h and then assessed them for cell migration and anchorage-independent colony formation. Ad-U1/SF and Ad-U1/Met inhibited cell migration by 60% and 56% (n=24), respectively ( Fig. 2A) , and inhibited colony formation in soft agar by 45% and 67% (n=24), respectively (Fig. 2B) . These results indicate that transient expression of anti-SF and anti-c-met U1/ribozymes inhibits the malignant phenotype of U-87 MG cells in vitro.
In vivo knock-down of SF/HGF and c-met expression inhibits the growth of established s.c. glioblastoma xenografts
We established U-87 MG human glioblastoma xenografts s.c. in immunodeficient mice. When the tumors reached a size of ~50 mm 3 , we injected them twice per week with liposomes complexed with either anti-SF/HGF expression plasmids (pU1/SF), anti-c-met U1/ribozyme expression plasmids (pU1/Met), a combination of both, or liposomes complexed with control plasmid (pU1). We measured tumor size before each injection for 21 days. Alternatively, we treated animals with established s.c. xenografts with intravenous injections of liposome-DNA complexes every 10 days and monitored tumor size for 30 days. We also extracted total RNA from the latter tumors to assess the effect of U1/ribozymes on SF/HGF and c-met mRNA.
Control xenografts directly injected with liposomes only or with pU1 liposomes grew 24-and 23-fold, respectively. In contrast, tumor xenografts injected with pU1/SF and pU1/Met liposomes grew only 3.4-and 2.6-fold, respectively (n=8) (P<0.01) (Fig. 3A) . Tumor growth in animals that received i.v. injections of either pU1/SF or pU1/Met liposomes was decreased but not statistically significantly, whereas tumors in animals that received a combination of pU1/SF and pU1/met liposomes were 79% (n=8) smaller than controls (P<0.05) (Fig. 3B ).
To assess in vivo knock-down of SF/HGF and c-met expression, we treated animals bearing established s.c. glioma xenografts with two i.v. injections of either pU1/SF, pU1/Met or pU1 control liposomes. Analysis of total tumor RNA by quantitative Light Cycler RT-PCR showed that in vivo delivery of either pU1/SF or pU1/Met liposomes inhibited SF/HGF and c-met expression, respectively, based on a shift in Light Cycler PCR product amplification curves by 3-10 cycles (n=5) for SF/HGF and 2 cycles (n=4) for c-met, when compared with control-injected animals (Fig.  3C) . GAPDH mRNA levels, measured in the same tumors and by the same method, were unchanged (Fig. 3C) .
In vivo inhibition of SF/HGF and c-met expression promotes apoptosis and inhibits tumor cell proliferation and tumor angiogenesis
To dissect the mechanisms by which anti-SF and anti-c-met U1/ribozymes inhibit in vivo tumor growth, we treated animals bearing s.c. tumor xenografts i.v. with U1/ribozymes and then analyzed tumors for changes in apoptosis and angiogenesis, factors known to be affected by SF/HGF-c-met signaling. Histological sections stained with hematoxylin and eosin revealed zones of necrosis and fibrosis and an increased number of apoptotic bodies in tumors treated with pU1/SF or pU1/Met liposomes. Immunohistochemistry showed that the number of cells expressing activated caspase-3, a marker of apoptosis, was increased by 5.3-fold and 6-fold (P<0.001) in tumors treated with pU1/SF and pU1/Met liposomes, respectively (Fig. 4) . Tumor angiogenesis, based on blood vessel density, was inhibited by 43% and 38% (P<0.001) in tumors treated with pU1/SF and pU1/Met liposomes, respectively (Fig. 4) .
In vivo delivery of U1/ribozymes via adenoviruses or liposome-DNA complexes inhibits the growth of established intracranial glioblastoma xenografts
We implanted U-87 MG human glioblastoma cells within the caudate/putamen of nude mice and 4 days later began either intratumoral or i.v. treatment with control or anti-SF and anti-c-met U1/ribozyme expression vectors. We performed direct intratumoral stereotactic injections of Ad-U1/SF and Ad-U1/Met or control Ad/U1 (n=20) every 5 days and sacrificed animals on postimplantation day 18 for histological assessments. Alternatively, we administered liposomes complexed with either pU1/SF and pU1/Met or with control pU1 i.v. every 10 days (n=10), and animals were sacrificed on postimplantation day 18. We found significant antitumor responses regardless of route of administration or expression vector used (Fig. 5 ). Tumors were 3-fold smaller (P<0.05) in response to direct intratumoral ribozyme delivery (Fig. 5A ) and 23-fold smaller (P<0.01) in response to i.v. delivery (Fig. 5B) . Also, only 10 of 20 animals receiving intratumoral ribozymes had histologically detectable tumors compared with 17 of 20 controls. Seven of 10 animals receiving i.v. ribozymes had detectable tumors compared with 10 of 10 controls. Thus, various potential strategies exist for delivering U1/ribozymes for brain tumor gene targeting.
In vivo knock-down of SF/HGF and c-met expression in human glioblastoma xenografts promotes animal survival
We implanted human glioblastoma cells intracranially and, beginning 4 days later, treated animals i.v. with liposome-U1/ribozyme complexes as described previously. Animal survival was then examined. Animals treated with pU1/SF + pU1/met liposomes showed a 27% increase in median survival compared with controls (n=10; P<0.01) (Fig. 5C ). One animal in the pU1/SF and pU1/met liposome group survived more than 60 days, after which it was sacrificed. These results indicate that in vivo targeting of the SF/HGF-c-met signaling pathway can prolong survival of glioma-bearing animals.
DISCUSSION
Innovative strategies for inhibiting cellular/molecular pathways of malignancy are desperately needed. The multifunctional growth factor SF/HGF and its receptor c-met compose one such pathway in multiple human malignancies, including glioblastoma. Recently, neutralizing monoclonal antibodies to SF/HGF displayed antitumor activity in animal models by inhibiting autocrine c-met activation (19) . We demonstrate for the first time that in vivo inhibition of SF/HGF and c-met expression can inhibit the growth of human glioma xenografts that express an intact autocrine SF/HGF-c-met signaling pathway. We also show for the the first time that chimeric U1snRNA/ribozymes can be used in vivo for protooncogene targeting in systemic as well as intracranial neoplasms. Components of our chimeric transgene derived from U1snRNA, a member of the endogenous mammalian spliceosome complex, include a constitutively active mammalian promoter that enhances levels of expression, 5' and 3' stable stem loops with high GC content that confer resistance to exonucleases, and a trimethylguanosine 5' cap that enables accumulation in the nucleoplasm, where the newly transcribed mRNA molecules are most abundant (15, (20) (21) (22) (23) .
We previously showed that stable expression of the anti-SF/HGF and anti-c-met U1/ribozymes used in this study specifically inhibited targeted gene expression and protein levels by more than 95% (14) . Inhibition of target gene expression in the setting of transient U1/ribozyme expression as shown in this study is likely to be vital for most clinical applications. The fact that the degree of reduction in levels of SF/HGF and c-met protein was modest relative to mRNA levels after only 48 h of transient U1/ribozyme expression in vitro is expected given the relatively longer protein half-lifes. Note that we show that even transient U1/ribozyme-mediated inhibition of SF/HGF expression to the levels observed in this study can have functional consequences as evidenced by reduced autocrine cmet receptor activation and inhibited glioma cell migration and anchorage-independent growth. The potential limitations of transient U1/ribozyme expression can be compensated for by repeated and longer administration of U1/ribozymes and justify more detailed in vivo pharmacokinetic analyses.
We identified at least two potential mechanisms for the antitumor response to the anti-SF/HGF and anti-Met U1/ribozymes. SF/HGF is a potent angiogenic factor with expression levels correlating with angiogenic indices in human gliomas (24) (25) (26) . Tumors treated with U1/ribozymes contained approximately 40% fewer blood vessels than did controls, which is consistent with an antiangiogenic tumor response. Most interesting were our findings that U1/ribozyme-treated tumors contained zones of necrosis and fibrosis, with a dramatic elevation in tumor cell apoptosis based on the identification of apoptotic bodies and a five-to sixfold increase in the number of tumor cells expressing activated caspase-3, a downstream effector of apoptosis (27) .
SF/HGF-c-met signaling inhibits the ability of cytotoxic therapies to induce apoptosis in neoplastic cells, including glioma via a PI3-kinase/AKT-dependent pathway (16, 28, 29) . Our findings suggest that inhibiting the SF/HGF-c-met pathway can induce glioma cell apoptosis in vivo even in the absence of cytotoxic therapy. Our results also strongly suggest that in vivo anti-SF/HGF and anti-cmet U1/ribozyme therapy can provide a biological window of opportunity for enhancing tumor responses to radio/chemotherapy, similar to our previous findings in cultured glioma cells. We are confident that the therapeutic responses observed in these studies result from U1/ribozyme action based on the absence of an antitumor effect in animals treated with control pU1 liposomes and the verification of target gene expression inhibition in tumor tissue by using real-time RT-PCR.
The ability of liposome-U1/ribozyme complexes to inhibit tumor growth and expression of the targeted genes is consistent with some degree of liposome-DNA penetration into tumor parenchyma (30) . However, the relative contribution of antiangiogenesis as a result of U1/ribozyme inhibition of c-met expression in tumor endothelial cells vs. their direct effect on glioma cells is uncertain. Our i.v. dosing schemes were chosen to minimize nonspecific antitumor host responses that can result from vector-derived bacterial DNA sequences containing hypomethylated CpG motifs (31) (32) (33) . Although such a "bystander" host response is not sufficient by itself to cause the antitumor responses observed, we can not rule out that it is a requirement. In addition, the antitumoral effect achieved when U1/ribozymes are delivered via adenoviruses indicates that, independent of the mode of delivery, the transgenes exert a specific inhibitory effect.
Our finding of substantial antitumor responses to i.v. anti-SF/HGF and anti-Met U1/ribozymes is particularly important to future potential clinical applications. Human malignant gliomas are highly infiltrative neoplasms not curable with even the most aggressive local therapies available. Thus, novel molecular and biological therapeutics broadly deliverable to brain regions known to contain microinvasive glioma cells will likely have the highest therapeutic impact. Intravenous delivery allows for flexible prolonged dosing either alone or in conjuncton with conventional radio/chemotherapeutic cytotoxic therapy. Furthermore, i.v. efficacy suggests that anti-SF/HGF and anti-c-met U1/ribozymes may be developed against common systemic malignancies whose metastatic potential is associated with aberrant c-met signaling. 3 , they were injected directly with pU1/SF, pU1/Met, pU1 (control) liposomes, or with liposomes only, and tumor sizes were monitored. Xenografts injected with liposomes only or with pU1 liposomes grew 24-and 23-fold, respectively, whereas tumor xenografts injected with pU1/SF and pU1/Met liposomes grew only 3.4-and 2.6-fold, respectively (P<0.01). B) U-87 MG human glioblastoma xenografts were implanted subcutaneously in immunodeficient mice, and the animals were injected intravenously with pU1/SF, pU1/Met, pU1/SF + pU1/Met, or pU1 (control) liposomes. Xenografts in animals that received i.v. injections of combined pU1/SF + pU1/met liposomes were significantly smaller (78%) than in controls (P<0.05). C) Total RNA was extracted from tumors of animals treated with intravenous liposome-DNA complexes as in B. SF/HGF and c-met mRNA were quantified using light-cycler RT-PCR. The representative results show a shift of light-cycler PCR product amplification curves by three additional cycles for SF/HGF in animals that received pU1/SF liposomes and a shift of two more cycles for c-met in animals that received pU1/Met liposomes relative to animals injected with pU1 (control) liposomes. GAPDH amplification curves, measured in the same tumors and by the same method, were unchanged. 
